Barely Significant
← all phrases

“showed a trend”

53,323 sentences · 53,323 papers · 65,371 search hits before verification

In the literature

Additionally, analysis of The Cancer Genome Atlas (TCGA) database ( 34 , 35 ) further indicated that patients with high IL9 expression showed a trend for better overall survival, although not statistically significant, compared with those with low IL9 expression in tumor tissues with high CD8 + infiltration in human melanoma (skin cutaneous melanoma), colon cancer, and breast cancer ( Supplemental Figure 4A ).
reported that 10 sessions of 2 mA anodic tDCS of the primary motor cortex combined with robot-assisted arm training in patients with chronic incomplete SCI showed a trend toward improved arm and hand performance compared with the sham tDCS group. 35 Potter-Baker et al. also reported that 10 sessions of 2 mA anodal tDCS of the primary motor cortex combined with upper limb training in patients with chronic incomplete SCI resulted in improved upper limb muscle strength and plastic changes in the upper limb motor-related cortex. 36 Cortes et al. investigated the effects of one session of 1 mA, 2 mA, or sham tDCS of the primary motor cortex on upper limb motor performance in patients with chronic cervical SCI.
PEDVs were suspended on each polymer-coated PPE for 1 h at 4 °C, and their antiviral activity was assessed by measuring TCID 50 values of viable viruses remaining both in solution and on the coated surfaces ( Figure 5 A). Viruses remaining on the surfaces were detached by gentle vortexing. Interestingly, poly(DMA-PEGMA-QA)-coated PPE surfaces showed a trend in antiviral activity different from that obtained using an aqueous solution of the polymers, which showed considerable antiviral activity regardless of monomer ratio.
In this study, although our six patients with EBV ( +) gastric cancer (5 in the nivolumab and 1 in the placebo group) also showed a trend toward a high percentage (4/6, 66.7%) of tumor PD-L1 CPS (≥ 1%) compared with those of patients with EBV ( −) gastric cancer (9/30, 30%), 2 out of 5 EBV ( +) patients in the nivolumab group showed early progressive disease (Figure S 2 ).